Modifications of therapeutic proteins: challenges and prospects
- 1 April 2007
- journal article
- Published by Springer Nature in Cytotechnology
- Vol. 53 (1-3) , 121-125
- https://doi.org/10.1007/s10616-007-9075-2
Abstract
The production of therapeutic proteins is one of the fastest growing sectors of the pharmaceutical industry. However, most proteins used in drug therapy require complex post-translational modifications for efficient secretion, drug efficacy and stability. Common protein modifications include variable glycosylation, misfolding and aggregation, oxidation of methionine, deamidation of asparagine and glutamine, and proteolysis. These modifications not only pose challenges for accurate and consistent bioprocessing, but also may have consequences for the patient in that incorrect modifications or aggregation may lead to an immune response to the protein therapeutic. This review provides examples of analytical and preventative advances that have been devised to meet these challenges, and insights into how further advances can improve the efficiency and safety in manufacturing recombinant proteins.Keywords
This publication has 37 references indexed in Scilit:
- Commercial interest grows in glycan analysisNature Biotechnology, 2007
- Immunomics: discovering new targets for vaccines and therapeuticsDrug Discovery Today, 2006
- The role of glutathione in disulphide bond formation and endoplasmic‐reticulum‐generated oxidative stressEMBO Reports, 2006
- In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferaseBiotechnology & Bioengineering, 2005
- Control of rHuEPO biological activity: The role of carbohydrateExperimental Hematology, 2004
- Characterizing biological products and assessing comparability following manufacturing changesNature Biotechnology, 2004
- Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti‐melanoma mouse IgG3 monoclonal antibody R24Biotechnology & Bioengineering, 2003
- High affinity capture surface for matrix‐assisted laser desorption/ionisation compatible protein microarraysRapid Communications in Mass Spectrometry, 2003
- Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro MixturesClinical Pharmacokinetics, 2002
- Oxidation of either methionine super351 or methionine super358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activityJournal of Biological Chemistry, 2000